Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma ...
In connection with Spark’s overhaul, Roche will incur approximately $2.4 billion in goodwill impairment costs. This sum takes ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) ...
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Roche is to buy gene therapy firm Spark Therapeutics for $4.8 billion, adding an already-approved treatment for inherited blindness to its portfolio, and boosting its pipeline with a series of ...
Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...
SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback